Angiogen is a privately held biopharmaceutical discovery company developing novel therapies for treating cancerous solid, vascular tumors. Angiogen's scientific team has world-recognized expertise and experience in angiogenesis inhibition, especially as it relates to the disease of cancer. Angiogen's first therapy, currently in a Phase I clinical trial, is based upon combining two classes of FDA approved drugs into one anti-angiogenesis cancer- fighting treatment. Three major biopharmaceutical companies have provided support for Angiogen's clinical research. Angiogen continues to explore other diagnostic tests and drug candidates related to its work in angiogenesis field offering hope to the approximately 5 million people worldwide who will die annually from metastatic cancer (555,000 in US)
